UB Paderborn / Katalog / Suche / in CDI

Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo-controlled, multicenter clinical trial

The Journal of thoracic and cardiovascular surgery, 2013-10, Vol.146 (4), p.927-939

2013

Volltextzugriff (PDF)

Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trial

The American heart journal, 2014-08, Vol.168 (2), p.197-204.e4

2014

Volltextzugriff (PDF)

Safe Application of a Restrictive Transfusion Protocol in Moderate-Risk Patients Undergoing Cardiac Operations

The Annals of thoracic surgery, 2014-05, Vol.97 (5), p.1630-1635

2014

Volltextzugriff (PDF)

High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease

European heart journal, 2009-05, Vol.30 (9), p.1066-1072

2009

Volltextzugriff (PDF)

Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart disease

Journal of clinical epidemiology, 2012-04, Vol.65 (4), p.444-453

2012

Volltextzugriff (PDF)

Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. A preliminary report

Thrombosis and haemostasis, 2009-10, Vol.102 (4), p.765

2009

Volltextzugriff (PDF)

Excess Sudden Cardiac Deaths after Short-Term Clarithromycin Administration in the CLARICOR Trial: Why Is This So, and Why Are Statins Protective?

Cardiology, 2011-01, Vol.118 (1), p.63-67

2011

Volltextzugriff (PDF)

Myocardial Stress in Patients with Acute Cerebrovascular Events

Cardiology, 2008-01, Vol.110 (2), p.123-128

2008

Volltextzugriff (PDF)

High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial

Scandinavian journal of clinical and laboratory investigation, 2011-02, Vol.71 (1), p.52-62

2011

Volltextzugriff (PDF)

Clarithromycin for 2 Weeks for Stable Coronary Heart Disease: 6-Year Follow-Up of the CLARICOR Randomized Trial and Updated Meta-Analysis of Antibiotics for Coronary Heart Disease

Cardiology, 2008-01, Vol.111 (4), p.280-287

2008

Volltextzugriff (PDF)

Statin Treatment Prevents Increased Cardiovascular and All-Cause Mortality Associated With Clarithromycin in Patients With Stable Coronary Heart Disease

Journal of cardiovascular pharmacology, 2010-02, Vol.55 (2), p.123-128

2010

Volltextzugriff (PDF)

Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial

Diagnostic microbiology and infectious disease, 2010-04, Vol.66 (4), p.385-392

2010

Volltextzugriff (PDF)

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial

BMJ (British Medical Journal), 2006-01, Vol.332 (7532), p.22-24

International edition, 2006

Volltextzugriff (PDF)

influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease

Inflammation research, 2011-03, Vol.60 (3), p.281-287

2011

Volltextzugriff (PDF)

Verapamil in acute myocardial infarction. The rationales of the VAMI and DAVIT III trials

Cardiovascular drugs and therapy, 1999-07, Vol.13 (4), p.301-307

JESPERSEN, C. M

1999

Volltextzugriff (PDF)

Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial

Scandinavian journal of clinical and laboratory investigation, 2014-11, Vol.74 (8), p.657-664

2014

Volltextzugriff (PDF)

Anti-ischemic intervention as prognosis improvement in patients with coronary artery disease, with special focus on verapamil

The American journal of cardiology, 1996-06, Vol.77 (16), p.32D-36D

JESPERSEN, C. M

1996

Volltextzugriff (PDF)

Verapamil and angiotensin-converting enzyme inhibitors in patients with coronary artery disease and reduced left ventricular ejection fraction

The American journal of cardiology, 1996-06, Vol.77 (16), p.16D-21D

1996

Volltextzugriff (PDF)

Detection of myocardial ischaemia by transthoracic leads in ambulatory electrocardiographic monitoring

British Heart Journal, 1992-09, Vol.68 (9), p.286

1992

Volltextzugriff (PDF)

The Effect of Verapamil on Major Events in Patients with Exercise-Induced Ischemia Recovering from Acute Myocardial Infarction: A Review

Journal of cardiovascular pharmacology, 1991, Vol.18 Suppl 6, p.30-32

Jespersen, Christian M

1991

Volltextzugriff (PDF)

The small blue pills

Ugeskrift for læger, 2002-09, Vol.164 (36), p.4203

Jespersen, Christian M

2002

Volltextzugriff (PDF)

AMI – ‘Acquired Microbe Invasion’?

Heart drug, 2004, Vol.4 (2), p.101-102

Jespersen, Christian M.

2004

Volltextzugriff (PDF)

Antimischemic intervention as prognosis improvement in patients with coronary artery disease, with special focus on verapamil

The American journal of cardiology, 1996-06, Vol.77 (16), p.32D-36D

Jespersen, Christian M.

1996

Volltextzugriff (PDF)

Verapamil in acute myocardial infarction. the rationales of the VAMI and DAVIT III trials

Cardiovascular drugs and therapy, 2000-02, Vol.14 (1), p.99-105

JESPERSEN, C. M

2000

Volltextzugriff (PDF)

Effects of Natural Oestrogen Therapy on Blood Pressure and Renin-angiotensin System in Normotensive and Hypertensive Menopausal Women

Journal of hypertension, 1983-12, Vol.1 (4), p.361-364

1983

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: A randomized, placebo-controlled, multicenter clinical trial

Agreement between public register and adjudication committee outcome in a cardiovascular randomized clinical trial

Safe Application of a Restrictive Transfusion Protocol in Moderate-Risk Patients Undergoing Cardiac Operations

High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease

Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart disease

Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. A preliminary report

Excess Sudden Cardiac Deaths after Short-Term Clarithromycin Administration in the CLARICOR Trial: Why Is This So, and Why Are Statins Protective?

Myocardial Stress in Patients with Acute Cerebrovascular Events

High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial

Clarithromycin for 2 Weeks for Stable Coronary Heart Disease: 6-Year Follow-Up of the CLARICOR Randomized Trial and Updated Meta-Analysis of Antibiotics for Coronary Heart Disease

Statin Treatment Prevents Increased Cardiovascular and All-Cause Mortality Associated With Clarithromycin in Patients With Stable Coronary Heart Disease

Chlamydia pneumoniae IgG and IgA antibody titers and prognosis in patients with coronary heart disease: results from the CLARICOR trial

Randomised placebo controlled multicentre trial to assess short term clarithromycin for patients with stable coronary heart disease: CLARICOR trial

influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease

Verapamil in acute myocardial infarction. The rationales of the VAMI and DAVIT III trials

Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trial

Anti-ischemic intervention as prognosis improvement in patients with coronary artery disease, with special focus on verapamil

Verapamil and angiotensin-converting enzyme inhibitors in patients with coronary artery disease and reduced left ventricular ejection fraction

Detection of myocardial ischaemia by transthoracic leads in ambulatory electrocardiographic monitoring

The Effect of Verapamil on Major Events in Patients with Exercise-Induced Ischemia Recovering from Acute Myocardial Infarction: A Review

The small blue pills

AMI – ‘Acquired Microbe Invasion’?

Antimischemic intervention as prognosis improvement in patients with coronary artery disease, with special focus on verapamil

Verapamil in acute myocardial infarction. the rationales of the VAMI and DAVIT III trials

Effects of Natural Oestrogen Therapy on Blood Pressure and Renin-angiotensin System in Normotensive and Hypertensive Menopausal Women

Suchergebnisse filtern